Last reviewed · How we verify
Gemcitabine, Docetaxel, Capecitabine — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Gemcitabine, Docetaxel, Capecitabine (Gemcitabine, Docetaxel, Capecitabine) — Columbia University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gemcitabine, Docetaxel, Capecitabine TARGET | Gemcitabine, Docetaxel, Capecitabine | Columbia University | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Gemcitabine, Docetaxel, Capecitabine CI watch — RSS
- Gemcitabine, Docetaxel, Capecitabine CI watch — Atom
- Gemcitabine, Docetaxel, Capecitabine CI watch — JSON
- Gemcitabine, Docetaxel, Capecitabine alone — RSS
Cite this brief
Drug Landscape (2026). Gemcitabine, Docetaxel, Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-docetaxel-capecitabine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab